Related Experiment Video
Updated: Apr 25, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Novel treatment approaches in hypertensive type 2 diabetic patients
Yaniel Castro Torres1, Richard E Katholi1
1Yaniel Castro Torres, Facultad de Medicina, Universidad de Ciencias Médicas Dr. Serafín Ruiz de Zárate Ruiz, Santa Clara 50100, Villa Clara, Cuba.
Insights
Managing type 2 diabetes mellitus (T2DM) and hypertension is crucial for preventing cardiovascular disease. Carvedilol and renal denervation show promise in lowering blood pressure and glucose, but individualized treatment is key.
Area of Science:
- Cardiology
- Endocrinology
- Nephrology
Background:
- Type 2 diabetes mellitus (T2DM) and hypertension are prevalent global conditions.
- Their co-occurrence increases cardiovascular disease risk, necessitating prioritized clinical management.
- Effective control of both conditions is vital for improving patient prognosis.
Purpose of the Study:
- To evaluate carvedilol and renal denervation as therapeutic options for hypertensive patients with T2DM.
- To explore their potential in reducing plasma glucose and blood pressure.
- To investigate their role in mitigating future complications and enhancing clinical outcomes.
Main Methods:
- Investigating the pathophysiological mechanisms of carvedilol and renal denervation.
- Focusing on the attenuation of sympathetic nervous system activity as a key mechanism.
- Analyzing the impact on blood pressure and insulin sensitivity.
Main Results:
- Both carvedilol and renal denervation demonstrate potential in managing hypertensive T2DM.
- A reduction in sympathetic nervous system activity is a likely contributing factor.
- Improved insulin sensitivity and blood pressure control are observed.
Conclusions:
- Carvedilol and renal denervation offer promising therapeutic strategies for hypertensive T2DM patients.
- Individualized patient characteristics should guide treatment selection.
- Further research is required to establish optimal clinical application guidelines.
Abstract:
Type 2 diabetes mellitus (T2DM) and hypertension represent two common conditions worldwide. Their frequent association with cardiovascular diseases makes management of hypertensive patients with T2DM an important clinical priority. Carvedilol and renal denervation are two promising choices to reduce plasma glucose levels and blood pressure in hypertensive patients with T2DM to reduce future complications and improve clinical outcomes and prognosis. Pathophysiological mechanisms of both options are under investigation, but one of the most accepted is an attenuation in sympathetic nervous system activity which lowers blood pressure and improves insulin sensitivity. Choice of these therapeutic approaches should be individualized based on specific characteristics of each patient. Further investigations are needed to determine when to consider their use in clinical practice.
Related Concept Videos
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Hypertension IV: Drug Therapy and Lifestyle Modifications
Diabetes Mellitus: Type 2 and Gestational
Hypertension V: Nursing Management
Hypertension III: Clinical Manifestations and Diagnostic Studies
Hypertension II: Pathophysiology
